• Heparin-protamine balance (HPB) modulates bleeding after neonatal cardiopulmonary bypass (CPB).
Essentials
• Heparin-protamine balance (HPB) modulates bleeding after neonatal cardiopulmonary bypass (CPB).
• HPB was examined in 44 neonates undergoing CPB.
• Post-operative bleeding occurred in 36% and heparin rebound in 73%.
• Thrombin-initiated fibrin clot kinetic assay and partial thromboplastin time best assessed HPB.
Summary. Background: Neonates undergoing cardiopulmonary bypass (CPB) are at risk of excessive bleeding. Blood is anticoagulated with heparin during CPB. Heparin activity is reversed with protamine at the end of CPB. Paradoxically, protamine also inhibits blood coagulation when it is dosed in excess of heparin. Objectives:
To evaluate heparin-protamine balance in neonates undergoing CPB by using research and clinical assays, and to determine its association with postoperative bleeding. Patients/Methods: Neonates undergoing CPB in the first 30 days of life were studied. Blood samples were obtained during and after surgery. Heparin-protamine balance was assessed with calibrated automated thrombography, thrombin-initiated fibrin clot kinetic assay (TFCK), activated partial thromboplastin time (APTT), anti-FXa activity, and thromboelastometry. Excessive postoperative bleeding was determined by measurement of chest tube output or the development of cardiac tamponade. Results and Conclusions: Of 44 neonates enrolled, 16 (36%) had excessive postoperative bleeding. The TFCK value was increased. By heparin in neonatal blood samples, but was only minimally altered by excess protamine. Therefore, it reliably measured heparin in samples containing a wide range of heparin and protamine concentrations. The APTT most closely correlated with TFCK results, whereas anti-FXa and thromboelastometry assays were less correlative. The TFCK and APTT assay also consistently detected postoperative heparin rebound, providing an important continued role for these longestablished coagulation tests in the management of postoperative bleeding in neonates requiring cardiac surgical repair. None of the coagulation tests predicted the neonates who experienced postoperative bleeding, reflecting the multifactorial causes of bleeding in this population.
Introduction
Bleeding after cardiac surgery requiring cardiopulmonary bypass (CPB) is a serious and relatively common complication. Neonates undergoing CPB are especially susceptible to bleeding [1] , with blood loss inversely correlating with age [2, 3] . They have a proportionately larger surface area exposed to bypass equipment and significant hemodilution that contribute to different postoperative hemostatic stress from that in adult CPB patients [4] . The neonatal coagulation system has decreased amounts of anticoagulant proteins [5, 6] and hyporeactive platelets [7] as compared with that of adult patients. These factors are thought to add to the increased bleeding tendency in neonatal patients undergoing cardiac surgery with CPB [8, 9] . Blood is anticoagulated with large doses of unfractionated heparin during CPB. A specific pentasaccharide sequence in heparin interacts with antithrombin (AT), inducing a conformational change that produces an approximately 10 000-fold increase in AT inhibitory activity towards factor Xa and thrombin [10] [11] [12] [13] . The activated clot time (ACT) is used to monitor heparin activity during CPB. Following CPB, the anticoagulant activity of heparin is reversed by administration of protamine, which is dosed on the basis of ACT monitoring [8] . Protamine strips heparin from AT, thereby decreasing its inhibitory activity towards FXa and thrombin. In addition to reversing the anticoagulant activity of heparin, protamine reduces platelet aggregation [14] and has intrinsic anticoagulant potential, mediated by inhibiting FV activation [15, 16] and decreasing FVII activation by tissue factor thrombin activity [16] . Clinical studies in adults have found that the administration of excess protamine following CPB is associated with postoperative bleeding [17, 18] . Additionally, protamine has a shorter plasma half-life than heparin [19] . Consequently, in the postoperative period, some patients can experience heparin rebound that should be recognized and treated.
As both heparin and protamine significantly affect coagulation, maintenance of a proper heparin-protamine balance is required for hemostasis following CPB [17, 18] . The ACT assay is a semi-automated assay used during the administration and reversal of heparin in which whole blood is mixed with a surface activator such as celite or kaolin, resulting in the activation of the intrinsic coagulation pathway. The ACT can be altered by hypothermia or hemodilution, and does not correlate well with heparin measurements made with anti-FXa activity assays [20] . Therefore, it may not accurately reflect heparin levels during CPB and after protamine reversal [20] . Several laboratory assays are available to monitor heparin and its reversal with protamine in patients undergoing CPB. The thrombin-initiated fibrin clot kinetic assay (TFCK) is a clotting assay that is highly sensitive to heparin and that measures the conversion of fibrinogen to fibrin following direct addition of thrombin to plasma. It does not require activation of the coagulation cascade, including FV, and therefore may be only minimally altered by protamine. A modified version of this assay has recently been used to examine the impact of fibrinogen carbamylation on fibrin clot formation [21] . The activated partial thromboplastin time (APTT) assay is a plasma clotting assay that is dependent on clotting factors of the intrinsic and common coagulation pathways. The APTT is prolonged in the presence of heparin, and is commonly used to monitor heparin therapy. However, it is also prolonged in the presence of protamine [22] . It has classically been used to monitor heparin anticoagulation in children, but it may underestimate their heparin levels, possibly because of the lower amounts of natural anticoagulants and faster clearance [5, 23] . The American College of Chest Physicians has recommended the use of the anti-FXa assay in conjunction with the APTT for monitoring heparin during treatment of thrombotic disease in children [24] , resulting in a trend towards the use of anti-FXa assays to confirm APTT-based heparin monitoring [25] . The anti-FXa assay is a plasma chromogenic test that measures inhibition of FXa by heparin-bound AT. The APTT assay and the anti-FXa assay correlate poorly, especially in samples obtained from children [26] treated with heparin or heparin followed by protamine. These discrepancies may be related to the function of the APTT assay as a screening test for multiple coagulation factors, in contrast to the anti-FXa assay, which is fairly specific for FXa. Thromboelastographic techniques use whole blood to examine the effect of heparin on clot formation and stability and are altered by excess protamine [27] . Calibrated automated thrombography (CAT) is a laboratory assay that continuously measures thrombin generation in plasma or platelet-rich plasma with a fluorescent thrombin substrate. A clotting profile is generated that provides an image of thrombin generation potential rather than simply providing a clotting time.
As the laboratory tests are affected differently by heparin and protamine, it can be difficult to accurately monitor heparin-protamine balance following CPB, particularly in neonates, who have a different hemostatic system from adults [5] [6] [7] . To address this difficulty, we examined heparin-protamine balance in neonates undergoing CPB in samples collected across the surgical procedure by using a research-based assay, i.e. CAT, and four clinical assays, i.e. the TFCK, the APTT assay, the antiFXa assay, and thromboelastography (TEG). The assays were compared for their ability to detect heparin reversal at the end of CPB and heparin rebound following surgery, and to predict postoperative bleeding.
Materials and methods

Study design
Neonatal patients requiring cardiac surgery with CPB within the first 30 days of life were enrolled after informed parental consent had been obtained. Exclusion criteria were birth weight of < 2.5 kg, a known inherited hemostatic abnormality, extracorporeal membrane oxygenation at the time of surgery, or a history of previous CPB. The study was approved by the Children's Hospital of Wisconsin Institutional Review Board.
Sample collection and processing
Blood was collected from arterial lines that were infused with 1 unit mL -1 heparin at 1-2 mL h -1 to prevent blood from clotting in the line. Before each blood sample collection, the first 1-2 mL of blood was discarded to remove the heparin in the line, and a new syringe was attached before drawing of the test sample. Whole blood samples used for this study were collected into 3.2% sodium citrate at two time points: (i) post-CPB samples, which were obtained after the patient was removed from the CPB pump and given protamine; and (ii) post-Op samples, which were obtained upon admission to the intensive care unit (an average of 147 AE 108 min after completion of CPB). Platelet-rich plasma (PRP) was obtained by centrifuging whole blood at 100 9 g for 10 min at 25°C. Plasma was subsequently obtained from PRP by centrifuging at 2500 9 g and 25°C. Pooled plasma from 13 healthy adults was used in some experiments.
Surgical hemostatic management and laboratory testing
An institutional transfusion strategy for neonatal congenital cardiac surgery requiring CPB was utilized for all patients. The CPB pump was primed with either whole blood, when available, or equal amounts of packed red blood cells (RBCs) and fresh frozen plasma. Upon initiation of rewarming but while, on the CPB pump cryoprecipitate and single-donor apheresis platelets were transfused.
Further transfusions in neonates with active bleeding were given to maintain the hematocrit above 35%, the platelet count above 100 9 10 3 lL À1 , the fibrinogen level above 200 mg dL À1 , and the prothrombin time below 1.5 times normal. Heparin management during CPB was monitored and titrated with the Medtronic Hepcon HMS Plus Hemostasis Management System (Medtronic, Minneapolis, MN, USA). A heparin dose between 300 units kg À1 and 800 units kg À1 as specified by the HMS device was administered before initiation of CPB, with the appropriate level of anticoagulation being maintained at a minimum activated clotting time of 480 s. The level of anticoagulation was measured every half-hour during CPB, with additional doses of heparin being administered as dictated by the HMS system. At the completion of CPB, the heparin was reversed with a dose of protamine specified by the HMS system. Another sample was run on the HMS system after protamine administration to ensure that there was no residual heparin effect.
Definition of postoperative bleeding
Excessive bleeding following CPB in neonates is often assessed by setting a specific threshold for chest tube output (CTO) [9] . In the current study, postoperative bleeding was defined according to one or more of the following criteria: ≥ 84 mL kg À1 total CTO in the first 24 h, ≥ 7 mL kg À1 h À1 CTO for two consecutive hours in the first 12 h, or re-exploration for bleeding or cardiac tamponade diagnosis in the first 24 postoperative hours [28] . The definition was derived from a retrospective cohort of pediatric patients and validated in a prospective cohort with recursive partitioning to evaluate different iterations of CTO over time postoperatively as predictors of RBC transfusion or re-exploration because of concerns about bleeding. To our knowledge, it is the only definition of excessive CTO that has been based on prediction of postoperative outcomes, including RBC transfusion in the first 24 postoperative hours and/or re-exploration because of concerns about tamponade or bleeding. ) divided by the TFCK value obtained in the absence of protamine in its absence.
Anti-FXa activity assay
The anti-FXa activity assay was performed with the Chromogenix Coamatic Heparin kit (Diapharma, West Chester Township, OH, USA), with minor modifications to accommodate small sample sizes. Plasma (1 : 25) and AT (0.04 U mL À1 ) were incubated according to the protocol. Anti-FXa activation in patient samples were compared with a standard curve generated with progressive amounts of unfractionated porcine heparin added to pooled adult plasma. 
Statistical analysis
Pearson's correlation was used to check the relationship between two continuous variables. Variables that were skewed were log-transformed. Two subjects had insufficient available plasma samples, and they were excluded from the analyses. A P-value of < 0.05 was considered to be statistically significant. The correlation analysis was performed with SAS 9.4 (SAS Institute, Cary, NC, USA). Receiver operating characteristic (ROC) analysis comparing the ability of the various assays to predict heparin rebound was carried out by the use of GRAPHPAD PRISM, with increased TFCK ratios in post-Op samples as compared with post-CPB samples as the outcome, and assays, including the APTT, CAT thrombin generation rate (TGR), TEG, and anti-FXa activity, as predictors.
Results
Study population
This prospective, observational study enrolled 44 neonates aged ≤ 30 days (median: 7 days) undergoing cardiac surgery with CPB for the first time to repair congenital heart defects. Baseline clinical parameters did not differ among patients with or without excessive bleeding ( Table 1) . The median Risk Adjustment Classification for Congenital Heart Surgery-1 (RACHS-1) score was 4, reflecting the high complexity of the cardiac procedures. Of the 44 neonates enrolled, 16 (36%) experienced excessive bleeding. The average CTOs in the first 24 postoperative hours were 294 mL in the bleeding group and 115 mL in the non-bleeding group. There were no unadjusted differences in age, birth weight, RACH-1 score, CPB time or amount of protamine administered between the bleeding and nonbleeding groups (Table 1 ). There was sufficient plasma to examine at least 43 post-CPB samples and 42 post-Op samples in all assays performed.
Effect of heparin-protamine balance on thrombin generation
Tissue factor-initiated CAT assays were used to investigate the effect of protamine on thrombin generation in neat and heparinized adult plasma. These experiments were designed to coincide with the estimated protamine plasma concentration in the neonates given to neutralize heparin and dosed using the ACT. The final plasma protamine concentration was estimated to range from 0.02 mg mL À1 to 0.2 mg mL À1 (average: 0.09 mg mL À1 ), on the basis of the total protamine given and the estimated blood volume of the neonate. Therefore, protamine was titrated into adult plasma from 0.0167 mg mL À1 to 0.333 mg mL À1 for CAT analyses. The thrombin generation profiles demonstrated a progressively increasing lag time and decreasing peak thrombin with increasing protamine concentration (Fig. 1A) . When protamine was titrated into heparinized plasma, it progressively neutralized the anticoagulant activity of 0.167 U mL À1 heparin and restored thrombin generation. The most efficient thrombin generation occurred at a heparin/protamine ratio of 3.34 U mg À1 (Fig. 1B) . A heparin/protamine ratio of 10 U mg À1 (excess heparin) or of ≤ 2 (excess protamine) resulted in decreased thrombin generation (Fig. 1B) , demonstrating the anticoagulant effect of excess protamine over heparin in these assays.
Evaluation of heparin-protamine balance with the TFCK
The thrombin time has a long history of diagnostic use in the clinical laboratory, and is particularly sensitive to heparin [30, 31] and its reversal with protamine [30, 32] . In the TFCK, addition of increasing amounts of heparin to adult plasma progressively decreased fibrin formation, with complete inhibition at ≥ 0.01 U mL À1 (Fig. 2A) . Its effectiveness for measuring heparin activity across a range of heparin/protamine ratios from 0.04 to 40 (U mg
À1
) was assessed in adult plasma. Protamine at 0.025 mg mL À1 effectively reversed the anticoagulant activity of heparin up to 1.0 U mL À1 (Fig. 2A) . The TFCK ratio increased with increasing heparin/protamine ratio between 0.04 and 4.0 (U mg
) with a particularly sensitive dynamic range between 0.1 and 0.4 U mg À1 (Fig. 2B) . The TFCK assay was performed following addition of protamine from 0.005 mg mL À1 to 0.075 mg mL À1 to either neat or heparinized (0.05 U mL À1 ) adult plasma. Up to 0.075 mg mL À1 protamine effectively reversed heparin anticoagulant activity without significantly altering the maximal rate of fibrin formation, demonstrating the minimal effect of protamine on the TFCK assay at these concentrations (Fig. 2C) . On the basis of these data, protamine at 0.025 mg mL À1 was added to neonatal plasma samples for determination of the TFCK ratio (as defined in Methods).
Comparison of TFCK ratio with CAT assay in neonatal samples
The TFCK ratio was used to measure heparin activity in all available post-CBP (n = 43) and post-Op (n = 42) samples. Insufficient available plasma prevented analysis of three samples. TFCK ratios were correlated with the respective TGR measured in CAT analyses of PRP, which served as an evaluation of global coagulation potential at each time point [33, 34] . The TGR inversely correlated with post-CBP (r = À 0.47, P = 0.0015) and post-Op (r = À 0.66, P < 0.0001) TFCK ratios, as blood samples containing the most heparin activity in the TFCK ratio generated the least amount of thrombin in both the non-bleeding and bleeding groups (Fig. 3A,B) . Correlation was much better in post-Op samples than in post-CPB samples. Lag time values and peak thrombin concentrations obtained in CAT analyses mirrored TGR correlations with the TFCK ratio ( Fig. 3C-F) , with correlations, again, being much better in the post-Op samples. On the basis of the studies with adult plasma shown in Figs 1 and 2 , and the correlation between the TFCK ratio and results from CAT assays with neonatal samples, the TFCK ratio was chosen as the assay of preference for comparison to the other clinical assays.
Correlations of the TFCK ratio with other clinical coagulation assays
TFCK ratios from all available post-CPB samples and post-Op samples were compared with three clinical assays: APTT, anti-FXa, and TEG (Fig. 4) . Correlations were stronger in post-Op samples than in post-CPB samples. The TFCK ratio correlated best with the APTT in post-Op samples (r = 0.70, P < 0.0001) (Fig. 4B) . The TFCK ratio correlated weakly with anti-FXa and most weakly with TEG clotting parameters in post-Op samples (Fig. 4D,F) . For additional comparison of the performances of the different clinical assays, scatterplots comparing the APTT, anti-FXa and TEG assays are provided in Fig. S1 . 
Postoperative heparin rebound
Postoperative heparin rebound was present in 75.6% of the neonates when defined as a higher post-Op TFCK ratio than post-CPB TFCK ratio (Fig. 5A) . No differences were found between the non-bleeding and bleeding groups. Additionally, the TFCK ratio was used as the outcome in ROC analysis to compare the ability of CAT TGR, APTT, anti-FXa and TEG to detect heparin rebound (Fig. 5B) . In this analysis, the APTT correlated best with the TFCK ratio for the detection of heparin rebound (area under the curve of 0.89, 95% confidence interval 0.78-0.99), followed by CAT TGR, TEG, and anti-FXa.
Association of heparin measurements with postoperative bleeding
None of the clinical assays, including the TFCK ratio, APTT, TEG, and anti-FXa, were significantly different in post-CPB or post-Op samples between bleeders and nonbleeders. However, large amounts of heparin were present according to the TFCK ratio in some post-Op samples from neonates with bleeding, suggesting that heparin rebound contributed to bleeding in this subset of patients (Fig. 5A ).
Discussion
Postoperative bleeding remains a common complication in neonates undergoing CPB, and occurred in 36% of those in this study. The management of hemostasis during and following CPB is complicated by individual variations in responsiveness to heparin and the accuracy of the ACT test for monitoring heparin [20] . Neonates present additional challenges, as their response to heparin therapy and protamine reversal differs from that of adults [35, 36] and has not been extensively studied. The current study showed that the TFCK ratio reliably measures heparin activity in adult samples spiked with heparin and protamine, as well as in neonatal post-CPB and post-Op blood samples containing a wide range of heparin and protamine concentrations. The APTT most closely correlated with TFCK ratio results, whereas anti-FXa and TEG assays were less correlative. In addition, we found that the TFCK ratio and APTT most consistently detected postoperative heparin rebound in the neonatal samples, providing an important continuing role for these long-established coagulation tests in the management of postoperative bleeding in neonates requiring cardiac surgical repair.
Monitoring of heparin reversal following CPB is difficult because heparin, protamine and heparin-protamine balance all alter most clinical coagulation assays. CAT assays were used here to evaluate how heparin and protamine alter the kinetics of thrombin production in plasma and PRP. Similar to results previously reported by Ni Ainle [15] , the addition of progressively larger amounts of either heparin or protamine to plasma progressively inhibited, and then totally blocked, thrombin generation in these assays, confirming their independent anticoagulant activities. In contrast to its anticoagulant activity in plasma lacking heparin, protamine enhanced The thrombin time assay has been used in clinical laboratories to reliably measure plasma heparin for decades [30] . The main difference between the TFCK and the thrombin time assay is that the former measures the kinetics of fibrin clot formation, whereas the latter measures the time to fibrin clot formation. Both the TFCK and the thrombin time assay are highly sensitive to heparin, because they directly measure the cleavage of fibrinogen to fibrin by thrombin, and the inhibition of this process by antithrombin-heparin, without the need to activate other clotting factors and without significant interference from other plasma protease inhibitors. The thrombin time has been found to be particularly useful for monitoring heparin in pediatric patients during the protamine reversal period, owing to the lack of correlation between APTT and antiFXa assays in children [26] . The experiments presented here characterized the impact of a wide range of concentrations of heparin and protamine on the TFCK, and showed only a minimal impact of protamine. Furthermore, the TFCK ratio correlated well with parameters derived from thrombin generation assays performed with neonatal plasma. Therefore, the TFCK ratio was chosen as the assay for comparison with other clinical coagulation assays for detection of heparin in plasma. In the context of the TFCK, it is most appropriate to consider heparin/protamine ratios, because both vary in the neonates studied. When the TFCK ratio is elevated, it is a specific indicator that there is excess heparin relative to protamine.
The correlation of the TFCK assay with the APTT, anti-FXa activity and TEG assays was examined in neonatal post-CPB and post-Op samples. The correlation between the assays was much better in post-Op samples than in post-CPB samples. It remains unclear why the assays correlated so differently with the TFCK ratio at the two time points. However, these data suggest that laboratory coagulation tests performed on samples taken in the time period immediately following CPB should be interpreted with caution and acted upon in the context of the clinical condition of the neonate. In post-Op samples, the TFCK ratio correlated more closely with the APTT than with the anti-FXa or TEG assays. Similarly, ROC analysis showed that the APTT identified heparin rebound most consistently with the TFCK ratio, whereas the anti-FXa activity and TEG assays were less consistent. The similarities between the TFCK ratio and the APTT may reflect the common measurement of fibrin formation as the endpoint for both assays, whereas dosedependent and age-dependent differences between anti-FXa and anti-FIIa assays have been reported to be particularly pronounced in infants as compared with older children [37] .
This study has several limitations, including distinct enrollment criteria and a surgical transfusion protocol that may differ from those used in other studies of heparin-protamine balance in neonates or children undergoing CPB. In addition, new guidelines for anticoagulation during CPB were recently published [38] . These guidelines are primarily for adult patients, owing to the limited amount of high-quality, evidence-based data available for pediatric patients. Therefore, extensive efforts to explain differences between our findings and those of others have not been made. Our findings and conclusions about testing for heparin-protamine balance and postoperative bleeding are directly applicable only to the population studied. In addition, none of the coagulation tests predicted the neonates who experienced postoperative bleeding. There were many neonates with normal coagulation test results who bled, reflecting the multifactorial causes of bleeding in the postoperative period. However, several of the patients with the highest TFCK ratio in the Post-Op samples bled, suggesting that heparin rebound contributed to bleeding in these patients. Thus, accurate identification and treatment of postoperative heparin rebound in neonates remains an important part of postoperative care. Another noteworthy limitation of this study is that heparin was infused into the arterial line used to draw test samples. Staff were trained to discard the first 1-2 mL of blood drawn from the line, to remove the heparin. However, it is unknown how rigorously this practice was actually followed. Therefore, the presence of heparin in some samples may represent that in the line rather than that in the patient; this could, perhaps, explain why some patients with high heparin levels did not bleed excessively, and may have contributed to the lack of correlation between some tests. Finally, given the small blood volume of neonates and their altered hemostatic system, the extent of reconstitution with adult plasma and cellular components is unknown. Despite these limitations, the data presented here suggest that the readily available APTT assay or TFCK are certainly adequate, and may be superior to the more expensive and difficult to obtain anti-FXa and TEG assays for monitoring neonates for heparin-protamine balance in the postoperative period. 
